MX2010005309A - Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor. - Google Patents

Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor.

Info

Publication number
MX2010005309A
MX2010005309A MX2010005309A MX2010005309A MX2010005309A MX 2010005309 A MX2010005309 A MX 2010005309A MX 2010005309 A MX2010005309 A MX 2010005309A MX 2010005309 A MX2010005309 A MX 2010005309A MX 2010005309 A MX2010005309 A MX 2010005309A
Authority
MX
Mexico
Prior art keywords
treatment
ion channels
oxopyrrolidin
benzenesulfonamide
thiazol
Prior art date
Application number
MX2010005309A
Other languages
English (en)
Inventor
Esther Martinborough
Dean Stamos
Timothy Neubert
Tara Whitney
Nicole Zimmermann
Mehdi Michel Djamel Numa
Aarti Sameer Kawatkar
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2010005309A publication Critical patent/MX2010005309A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención se relaciona con derivados heterocíclicos de la fórmula I, útiles como inhibidores de los canales iónicos. La invención también proporciona composiciones farmacéuticamente aceptables que comprenden los compuestos de la invención y métodos para usar las composiciones en el tratamiento de diferentes trastornos, por ejemplo, dolor; o una sal farmacéuticamente aceptable del mismo, en donde, independientemente para cada caso:El anillo Z es un tiazol o tiadiazol opcionalmente sustituido con 0-2 ocurrencias de R;V es CH2, NH, O o S; yR, R1, R2 y R3 son hidrógeno, alifático C1-C6, arilo, cicloalifático C3-C8, halo, CN, NO2, CF3, OCF3, OH, NH2, NH (alifático C1-C6), N (alifático C1-C6)2, COOH, COO (alifático C1-C6), O (alifático C1-C6), CHF2 o CH2F.
MX2010005309A 2007-11-13 2008-11-12 Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor. MX2010005309A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98748507P 2007-11-13 2007-11-13
US8814108P 2008-08-12 2008-08-12
PCT/US2008/083165 WO2009064747A2 (en) 2007-11-13 2008-11-12 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain

Publications (1)

Publication Number Publication Date
MX2010005309A true MX2010005309A (es) 2010-06-25

Family

ID=40380263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005309A MX2010005309A (es) 2007-11-13 2008-11-12 Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor.

Country Status (13)

Country Link
US (3) US7994166B2 (es)
EP (1) EP2231655B1 (es)
JP (1) JP2011503112A (es)
KR (1) KR20100098396A (es)
CN (1) CN102036985A (es)
AT (1) ATE522526T1 (es)
AU (1) AU2008321137A1 (es)
CA (1) CA2705336A1 (es)
IL (1) IL205697A0 (es)
MX (1) MX2010005309A (es)
NZ (1) NZ585332A (es)
RU (1) RU2010123781A (es)
WO (1) WO2009064747A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
CN101218226A (zh) * 2005-05-16 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
ZA200802977B (en) * 2005-09-09 2009-08-26 Vertex Pharma Bicyclic derivatives as modulators of voltage gated ion channels
CN101331115A (zh) * 2005-10-21 2008-12-24 沃泰克斯药物股份有限公司 调控离子通道的衍生物
MX2009012678A (es) 2007-05-25 2012-09-20 Vertex Pharma Moduladores de canal de ion y metodos de uso.
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
NZ585729A (en) * 2007-11-13 2012-04-27 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
NZ585332A (en) 2007-11-13 2012-05-25 Vertex Pharma 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain
EP2307412A2 (en) * 2008-07-01 2011-04-13 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
CN104136442B (zh) * 2012-01-16 2016-12-21 沃泰克斯药物股份有限公司 作为离子通道调节剂的吡喃‑螺环哌啶酰胺类
RU2015114405A (ru) 2012-10-12 2016-11-27 Ф. Хоффманн-Ля Рош Аг Замещенные соединения фенилкарбамата
WO2014060341A1 (en) 2012-10-16 2014-04-24 F. Hoffmann-La Roche Ag Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
EP3541373B1 (en) 2016-11-17 2023-11-01 Merck Sharp & Dohme LLC Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
KR20200030584A (ko) 2017-07-21 2020-03-20 앤타바이오 에스에이에스 화합물
CN113008999A (zh) * 2019-12-19 2021-06-22 重庆药友制药有限责任公司 一种分离测定氟比洛芬酯中2种基因毒性杂质的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU2004240885A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
AU2004263179B8 (en) 2003-08-08 2011-07-14 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
JP2007261945A (ja) * 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体
RU2007145434A (ru) * 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов ионных каналов
CN101218226A (zh) 2005-05-16 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
JP5112297B2 (ja) 2005-05-20 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なキノリン誘導体
WO2006133459A1 (en) * 2005-06-09 2006-12-14 Vertex Pharmaceuticals Incorporated Indane derivatives as modulators of ion channels
ZA200802977B (en) * 2005-09-09 2009-08-26 Vertex Pharma Bicyclic derivatives as modulators of voltage gated ion channels
JP2009511599A (ja) 2005-10-12 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体
CN101331115A (zh) * 2005-10-21 2008-12-24 沃泰克斯药物股份有限公司 调控离子通道的衍生物
KR20080081178A (ko) 2005-12-21 2008-09-08 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 헤테로사이클릭 유도체
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
MX2009012678A (es) 2007-05-25 2012-09-20 Vertex Pharma Moduladores de canal de ion y metodos de uso.
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
NZ585332A (en) 2007-11-13 2012-05-25 Vertex Pharma 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain
NZ585729A (en) * 2007-11-13 2012-04-27 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
EP2307412A2 (en) 2008-07-01 2011-04-13 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels

Also Published As

Publication number Publication date
NZ585332A (en) 2012-05-25
US7994166B2 (en) 2011-08-09
US20090131440A1 (en) 2009-05-21
US20120010416A1 (en) 2012-01-12
ATE522526T1 (de) 2011-09-15
CA2705336A1 (en) 2009-05-22
EP2231655B1 (en) 2011-08-31
KR20100098396A (ko) 2010-09-06
US8841282B2 (en) 2014-09-23
WO2009064747A3 (en) 2010-08-19
US20130338119A1 (en) 2013-12-19
EP2231655A2 (en) 2010-09-29
RU2010123781A (ru) 2011-12-20
CN102036985A (zh) 2011-04-27
IL205697A0 (en) 2010-11-30
JP2011503112A (ja) 2011-01-27
AU2008321137A1 (en) 2009-05-22
WO2009064747A2 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
MX2010005309A (es) Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor.
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
MX2010003009A (es) Piridil sulfonamidas como moduladores de canales ionicos.
ZA201003352B (en) Heterocyclic derivatives as modulators of ion channels
IL187382A0 (en) Bicyclic derivatives as modulators of ion channels
MX2010003865A (es) Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2010003866A (es) Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
NO20060518L (no) Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
MX2010003864A (es) Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2009011816A (es) Derivados de piridina.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MY161991A (en) Proteasome inhibitors
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MXPA05010496A (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FG Grant or registration